OR WAIT 15 SECS
New simulator to help refine animal testing and streamline pharmaceutical research.
Simcyp launches virtual ‘lab rat’ for drug development
New simulator to help refine animal testing and streamline pharmaceutical research
Sheffield, UK, 21 October 2008 … Simcyp Limited, the leader in modelling and simulation of drug-drug interactions in virtual human populations, today announces the launch of Simcyp Rat 2008, a ‘virtual animal’ for in silico prediction of drug kinetics.
Rats have been traditionally used in pharmaceutical development to examine how a compound is absorbed, distributed, metabolised and excreted by the body. Simcyp Rat can model these processes, providing crucial insights into how medicines will behave in real life.
Professor Amin Rostami-Hodjegan, Director of Research and Development at Simcyp Limited commented: “We have a great understanding of rat physiology which has allowed us to create algorithms and models which represent a virtual rat. Research scientists can now use their drug development data in simulations to predict how their medicine will behave in virtual animals. The system can even mimic real life experimental scenarios including whether rats are fed at the time of dosing and the amount of fluid that is administered with an oral dose.”
Dr Steve Toon, Executive Director at Simcyp, commented: “There is growing support within the pharmaceutical industry for alternative approaches to reduce, refine and replace animal testing while still maintaining high standards of research. Modelling and simulation is another tool which is now available to researchers who are trying to achieve these goals.”
The Simcyp Rat Simulator contains databases of commonly used drugs which allow the properties of new medicines to be compared with medicines that are already available. The Simulator is available to members of the Simcyp Consortium which includes nine of the top ten pharmaceutical companies worldwide.
Simcyp Limited provides a platform for pharmacokinetic modelling and simulation in virtual populations and is the world leader in the in silico prediction of metabolic drug-drug interactions. Simulations using Simcyp enable the characteristics of individuals at extreme risk from adverse reaction to be identified, and unnecessary drug exposure to human volunteers and animals to be minimised. The limitations of candidate compounds can be assessed and managed prior to human studies, allowing better focus of drug development resources.
The ‘Simcyp Population-based ADME Simulator’, ‘Simcyp Paediatric’ and ‘Simcyp Rat’ are licensed to the Simcyp Consortium (including Pfizer, Johnson &Johnson and AstraZeneca) and associated regulatory agencies including the US FDA. Academic licenses to support key research related to drug development have also been granted to centres of excellence in Europe, the USA and Japan. Simcyp also provides consultancy services, runs education programmes, and conducts internationally recognised leading-edge research and development.
Please visit our website: www.simcyp.com <http://www.simcyp.com